tradingkey.logo
tradingkey.logo
Search

Zenas Biopharma Inc

ZBIO
Add to Watchlist
31.440USD
-0.830-2.57%
Close 07-31 16:00ETQuotes delayed by 15 min
1.98BMarket Cap
LossP/E TTM

ZBIO Income Statement

You can find the annual or quarterly income statement of Zenas Biopharma Inc here for insights into the performance and operational efficiency of Zenas Biopharma Inc.
Quarterly
Quarterly+Annual
Quarterly
Annual
YOY
Hide blank rows
FY2026Q1
FY2025Q4
FY2025Q3
FY2025Q2
FY2025Q1
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022Q4
Total revenue
-100.00%0.00
-100.00%0.00
--0.00
--0.00
--10.00M
--5.00M
-100.00%0.00
----
----
--0.00
--50.00M
----
----
--0.00
Revenue
-100.00%0.00
-100.00%0.00
--0.00
--0.00
--10.00M
--5.00M
-100.00%0.00
----
----
--0.00
--50.00M
----
----
--0.00
Operating expenses
63.43%77.35M
17.63%71.31M
16.09%47.58M
38.94%55.16M
71.62%47.33M
144.65%60.62M
185.07%40.98M
110.01%39.70M
44.49%27.58M
30.49%24.78M
--14.38M
--18.91M
--19.09M
--18.99M
R&D expenses
73.10%60.44M
13.35%55.72M
2.60%34.40M
27.27%43.03M
54.18%34.91M
140.75%49.16M
258.49%33.53M
126.66%33.81M
47.55%22.64M
29.51%20.42M
--9.35M
--14.91M
--15.35M
--15.77M
Depreciation, depletion, and amortization
-73.91%6.00K
-69.70%10.00K
-69.44%11.00K
-65.71%12.00K
-30.30%23.00K
10.00%33.00K
38.46%36.00K
20.69%35.00K
17.86%33.00K
20.00%30.00K
--26.00K
--29.00K
--28.00K
--25.00K
Operating profit
-107.21%-77.35M
-28.21%-71.31M
-16.09%-47.58M
-38.94%-55.16M
-35.36%-37.33M
-124.48%-55.62M
-215.05%-40.98M
-110.01%-39.70M
-44.49%-27.58M
-30.49%-24.78M
--35.62M
---18.91M
---19.09M
---18.99M
Net non-operating interest income (expenses)
Non-operating interest income
--3.02M
--12.15M
----
----
----
----
----
----
----
----
----
----
----
----
Non-operating interest expense
--6.63M
--5.65M
--1.68M
----
----
----
----
----
----
----
----
----
----
----
Special income (expenses)
----
---166.67M
---5.00M
100.00%0.00
100.00%0.00
100.00%0.00
--0.00
98.48%-152.00K
---694.00K
---300.00K
--0.00
---10.00M
--0.00
--0.00
Other non-operating income (expenses)
-100.68%-24.00K
-356.82%-8.86M
16.06%2.76M
57.70%2.96M
652.54%3.55M
334.80%3.45M
14962.50%2.38M
1421.83%1.88M
4390.91%472.00K
15960.00%793.00K
---16.00K
---142.00K
---11.00K
---5.00K
Income before tax
-139.76%-80.99M
-360.63%-240.34M
-33.40%-51.50M
-37.46%-52.20M
-21.50%-33.78M
-114.84%-52.17M
-208.42%-38.61M
-30.74%-37.98M
-45.57%-27.80M
-27.86%-24.29M
--35.61M
---29.05M
---19.10M
---18.99M
Income tax
100.00%0.00
-75.29%106.00K
--0.00
--20.00K
---205.00K
42.52%429.00K
----
----
----
--301.00K
----
----
----
--0.00
Income after tax
-141.23%-80.99M
-357.08%-240.44M
-33.40%-51.50M
-37.51%-52.22M
-20.77%-33.57M
-113.95%-52.60M
-208.42%-38.61M
-30.74%-37.98M
-45.57%-27.80M
-29.45%-24.59M
--35.61M
---29.05M
---19.10M
---18.99M
Net income from continuous operations
-141.23%-80.99M
-357.08%-240.44M
-33.40%-51.50M
-37.51%-52.22M
-20.77%-33.57M
-113.95%-52.60M
-208.42%-38.61M
-30.74%-37.98M
-45.57%-27.80M
-29.45%-24.59M
--35.61M
---29.05M
---19.10M
---18.99M
Net income attributable to controlling interests
-141.23%-80.99M
-357.08%-240.44M
-33.40%-51.50M
-37.51%-52.22M
-20.77%-33.57M
-113.95%-52.60M
-208.42%-38.61M
-30.74%-37.98M
-45.57%-27.80M
-29.45%-24.59M
--35.61M
---29.05M
---19.10M
---18.99M
Net income attributable to common shareholders
-141.23%-80.99M
-357.08%-240.44M
-33.40%-51.50M
-37.51%-52.22M
-20.77%-33.57M
-113.95%-52.60M
-208.42%-38.61M
-30.74%-37.98M
-45.57%-27.80M
-29.45%-24.59M
--35.61M
---29.05M
---19.10M
---18.99M
Basic earnings per share
-81.28%-1.46
51.80%-4.53
-32.20%-1.22
-30.70%-1.25
-14.96%-0.80
-1420.62%-9.40
-203.26%-0.92
-30.74%-0.95
-45.57%-0.70
-29.45%-0.62
--0.89
---0.73
---0.48
---0.48
Diluted earnings per share
-81.28%-1.46
51.80%-4.53
-32.20%-1.22
-30.70%-1.25
-14.96%-0.80
-1420.62%-9.40
-203.26%-0.92
-30.74%-0.95
-45.57%-0.70
-29.45%-0.62
--0.89
---0.73
---0.48
---0.48
Dividend per share
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
Currency unit
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
Audit opinions
----
----
----
----
----
----
----
----
----
----
----
----
----
----

FAQs

How do I read Zenas Biopharma Inc's income statement on TradingKey?

Start with total revenue, then review cost of revenue, gross profit, operating expenses, operating profit, income before tax, net income, and EPS. Revenue shows the scale of the business, while margins and profit lines show whether that revenue is being converted into earnings efficiently.

What is the difference between quarterly and annual income statements?

A quarterly income statement shows performance for a three-month fiscal period, while an annual income statement summarizes the full fiscal year. Quarterly data is useful for tracking recent momentum and seasonality, while annual data is better for judging long-term growth, profitability, and business cycles.

What does YOY mean on the income statement page?

YOY means year over year. It compares a financial metric with the same period in the previous year, such as this quarter's revenue versus revenue in the same quarter last year. YOY comparison helps investors see growth trends while reducing the impact of normal seasonal changes.

Which income statement metrics matter most when analyzing ZBIO stock?

Important metrics include revenue growth, gross profit, gross margin, operating profit, operating margin, net income, EPS, R&D expenses, SG&A expenses, and tax expense. Investors usually look at these together to judge whether the company is growing, controlling costs, and improving profitability.

What was Zenas Biopharma Inc's revenue at year end?

Zenas Biopharma Inc reported 10.00M in revenue for fiscal year 2025, up from 5.00M in the previous year.

What was Zenas Biopharma Inc's net income for the year?

Zenas Biopharma Inc posted -377.74M in net income for fiscal year 2025.

How much net income did Zenas Biopharma Inc post in the last quarter?

Zenas Biopharma Inc reported -80.99M in net income for the latest quarter。

What was Zenas Biopharma Inc's annual operating profit?

Zenas Biopharma Inc's operating income was -211.38M for fiscal year 2025.

How is EPS related to the income statement?

EPS, or earnings per share, is based on net income divided by the number of shares outstanding. It helps investors understand how much profit the company generated for each share, but it should be reviewed alongside share count changes, margins, cash flow, and valuation metrics.
tradingkey.logo
Risk Warning: Our Website and Mobile App provides only general information on certain investment products. Finsights does not provide, and the provision of such information must not be construed as Finsights providing, financial advice or recommendation for any investment product.
Investment products are subject to significant investment risks, including the possible loss of the principal amount invested and may not be suitable for everyone. Past performance of investment products is not indicative of their future performance.
Finsights may allow third party advertisers or affiliates to place or deliver advertisements on our Website or Mobile App or any part thereof and may be compensated by them based on your interaction with the advertisements.
© Copyright: FINSIGHTS MEDIA PTE. LTD. All Rights Reserved.